SCHEMBL4924682

SCHEMBL4924682

CCCOc1ccc(-n2c(Cl)nc3cc(Cl)c(Cl)cc32)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 1/20 0.46
LMNA P02545 4/20 0.40
HTT P42858 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
DCTPP1 Q9H773 1/20 0.40
FGFR1 P11362 1/20 0.40
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 2/20 0.37
PTGS2 P35354 1/20 0.37
DHODH Q02127 1/20 0.37
QPCT Q16769 1/20 0.36
QPCTL Q9NXS2 1/20 0.36
MAPT P10636 2/20 0.36
RAD51 Q06609 1/20 0.36
PDE2A O00408 1/20 0.36
MAPK1 P28482 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4922249 0.95 CYP2D6 (0.41) CACNA2D1LMNASMN1; SMN2DCTPP1FGFR1
SCHEMBL4931085 0.89 CACNA2D1 (0.43) CACNA2D1LMNASMN1; SMN2DCTPP1ALDH1A1
SCHEMBL4927269 0.86 CACNA2D1 (0.48) CACNA2D1LMNAHTTSMN1; SMN2TSHR
SCHEMBL4934313 0.86 CACNA2D1 (0.45) CACNA2D1LMNAHTTSMN1; SMN2TSHR
SCHEMBL4933492 0.82 DCTPP1 (0.53) LMNAHTTSMN1; SMN2TSHRNPSR1
SCHEMBL4921791 0.81 PDE2A (0.49) CACNA2D1SMN1; SMN2DHODHMAPTPDE2A
SCHEMBL4927330 0.81 DCTPP1 (0.36) HTTNPSR1DCTPP1ALDH1A1PTGS2
SCHEMBL4931972 0.81 PDE2A (0.49) SMN1; SMN2FGFR1MAPTPDE2ACYP19A1
SCHEMBL4929856 0.79 P2RX3 (0.46) CACNA2D1LMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL4929752 0.79 HTT (0.44) LMNAHTTSMN1; SMN2NPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021069-A1 Receptor Function Regulating Agent GPR119, INSR, GPR65 CACNA2D1 3298/4885LMNA 4744/4885HTT 4035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.